Elon Musk’s latest The Insider turn is vintage Musk: audacious, unsettling, and just coherent enough to make everyone in the room check their assumptions. In his conversation with Zanny Minton Beddoes, he argued that AI and robots could make work optional, money less relevant, and deflation more likely than inflation in a world of extreme abundance.
What He Actually Said
The core claim is simple: if AI and robotics keep advancing fast enough, the economy could shift from scarcity to surplus, and prices could start bending downward rather than upward. Musk also suggested AI may surpass the sum of human intelligence in about five years, which is either a forecast or a warning label, depending on your portfolio and your pulse.
Why Investors Care
For investors, the real story is not whether money “matters” in 2036; it is which companies own the infrastructure of that future. Tesla (TSLA) is the obvious headline name, since Reuters reported Musk is pushing the company deeper into AI, robotics, and chip spending, while also reframing Tesla as more than an automaker. That matters because markets usually pay for optionality when the narrative becomes bigger than the current revenue line.
The Deflation Debate
Musk’s deflation thesis is provocative because it flips the usual AI inflation narrative on its head. His logic is that if robots and software massively expand the supply of goods and services, the price level could fall even as prosperity rises. That is a clean soundbite, but in practice the transition could be messy, with capital-heavy winners, labor-market dislocation, and plenty of policy friction along the way.
Winners And Watch List
The public-market beneficiaries would likely sit in three buckets: AI compute, robotics, and energy/infrastructure. That points investors toward names such as TSLA, NVDA, MSFT, GOOGL, and AMZN, which are all tied in different ways to the hardware, software, cloud, or deployment layer of AI. If Musk is right, the market may reward the companies that help build abundance before it starts handing out philosophical headaches.[7][6]
Wall Street Read
The sophisticated humor here is that Musk keeps describing a future where money becomes irrelevant while simultaneously helping create the most expensive arms race in modern business. Wall Street will happily suspend disbelief for a while, but only if the spreadsheets continue to show growth, not just prophecy. For now, the trade is less about believing 2036 will be cashless and more about recognizing that AI and robotics remain one of the market’s most powerful secular themes.
Learn More Now
The Sources
[1] An interview with Elon Musk | The Economist Insider https://www.economist.com/insider/the-insider/an-interview-with-elon-musk [2] Elon Musk’s vision of the future https://www.economist.com/business/2026/07/23/elon-musks-vision-of-the-future [3] Elon Musk says there’s a “good chance” China will be the … https://www.facebook.com/TheEconomist/videos/elon-musk-says-theres-a-good-chance-china-will-be-the-world-leader-in-ai-the-tes/2489912918099062/ [4] Elon Musk says only AI and robotics can solve the ‘insanely … https://finance.yahoo.com/news/elon-musk-says-only-ai-115028916.html [5] Elon Musk believes that Britain is heading for “a reckoning” … https://www.facebook.com/TheEconomist/posts/elon-musk-believes-that-britain-is-heading-for-a-reckoning-zanny-minton-beddoes-/1552181063607075/ [6] As Musk pivots beyond cars, Tesla’s autos engine is under … https://www.reuters.com/business/media-telecom/elon-musks-tesla-posts-cash-burn-capex-surges-ai-robotaxi-push-2026-07-22/ [7] Tesla lifts 2026 spending plans by a quarter as Musk funds … https://www.reuters.com/business/autos-transportation/tesla-revenue-misses-estimates-demand-weakens-2026-04-22/ [8] Elon Musk says AI and robotics will make money ‘irrelevant’ https://finance.yahoo.com/news/elon-musk-says-ai-robotics-213434560.html [9] Elon Musk predicts money will “stop being relevant” in the future https://www.youtube.com/watch?v=TzUed05edUg [10] 5 Key Takeaways From Elon Musk’s Latest Interview https://www.businessinsider.com/5-key-takeaways-from-elon-musks-latest-interview-2026-7 [12] The Economist on Instagram: ““Money won’t matter in 2036 … https://www.instagram.com/reel/DbNPAhVgfTx/ [13] Elon Musk on AI: humans will no longer be in control in ten … https://www.youtube.com/watch?v=1X-rr1DKSbY [14] The Economist on Instagram: “Elon Musk explains the … https://www.instagram.com/reel/DbLEq4lki-D/ [15] Elon Musk The Economist July 23rd 2026 – FULL Interview https://www.youtube.com/watch?v=8TjK-s0468w AISEOforBeginners/comments/1pp8fua/what_actually_makes_content_citationworthy_for_ai/ [17] I sat down with @ElonMusk for The Insider this week. … https://x.com/zannymb/status/2080235492524659150 [18] Elon Musk makes explosive claim over AI’s future https://www.facebook.com/WIONews/posts/30-to-36-months-mark-my-words-elon-musk-makes-explosive-claim-over-ais-future/1257520903153748/ [19] The Economist on Instagram: ““There really won’t be anything … https://www.instagram.com/reel/DbIY1MQj9ek/ [20] Perplexity , et al – Saul’s Investing Discussions https://discussion.fool.com/t/perplexity-et-al/121657 [21] Elon Musk speaks to ‘The Economist’: Editor-in-chief Zanny … https://www.youtube.com/watch?v=7trZGqCGOg8 [22] Elon Musk’s Humanoid Robot Claims ‘Unrealistic’ https://www.newsweek.com/elon-musk-claim-robots-outnumbering-humans-2040-unrealistic-1977949 [23] Elon Musk – “In 36 months, the cheapest place to put AI will be … https://www.youtube.com/watch?v=BYXbuik3dgA [24] Tesla raises spending plans, pours money into AI, chips and … https://www.reuters.com/video/watch/idRW477523042026RP1/ [25] AI Weekly: fakes, bots and job cuts | REUTERS https://www.youtube.com/watch?v=BsQxBO1fZVA [26] The Economist on Instagram: “Elon Musk says he “got too … https://www.instagram.com/reel/DbJU6_7lX8F/ [27] Tesla to have humanoid robots for internal use next year, … https://www.reuters.com/business/autos-transportation/tesla-have-humanoid-robots-internal-use-next-year-musk-says-2024-07-22/ [28] WEF 2026: Elon Musk says, Robots will outnumber Humans in … https://www.youtube.com/watch?v=mBDlcvyJh3k [29] “There really won’t be anything that AI can’t do better than … https://www.facebook.com/TheEconomist/videos/there-really-wont-be-anything-that-ai-cant-do-better-than-humans-apart-from-bein/1742747010094517/
Eli Lilly-backed Scribe Therapeutics is having the kind of debut that makes Wall Street reach for a second coffee: the CRISPR company priced an upsized IPO, then saw its shares jump sharply in trading, a rare show of enthusiasm for an early-stage gene-editing name. The company now trades under the ticker SCTX, while Eli Lilly trades as LLY.
Why investors are paying attention
Scribe is not a sleepy “wait-and-see” biotech story. It enters public markets with something most early gene-editing companies can only dream about: strategic backing and collaboration history with large pharma, including Eli Lilly and Sanofi (SNY), which gives the story more commercial gravity than a science-fair poster board. That matters because in biotech, validation from a major partner often functions like a seal of approval, or at least a very expensive thumbs-up.
The story behind the surge
The market’s reaction reflects more than just IPO appetite; it reflects demand for differentiated platforms in a sector where investors increasingly want both innovation and a plausible path to value creation. Scribe’s pitch is centered on engineered CRISPR technologies and the promise of durable genetic medicines, which has enough long-term appeal to keep both scientists and speculators awake. The company also comes to market after a period of constructive momentum around its collaborations, including milestone progress tied to Lilly-linked programs.
What makes it investable
For investors, the appeal is straightforward: an early public biotech with marquee backing, a platform story, and a category that still commands attention when execution looks credible. The risk is equally straightforward: this is still an early-stage company, and the path from promising science to durable cash flow is long, expensive, and often littered with clinical potholes. In other words, it has the glamour of frontier biotech with the financial personality of a startup that has not yet met gravity.
Market takeaway
Scribe’s IPO is a reminder that biotech investors still love a story with three ingredients: deep-pocketed sponsors, a platform with scientific ambition, and a market willing to reward scarcity. If the listing holds up, it may signal that selective risk appetite is returning to gene editing, especially when a name arrives with LLY in the background and SCTX on the tape.
The Sources
[1] Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO https://www.bloomberg.com/news/articles/2026-07-24/eli-lilly-backed-scribe-therapeutics-jumps-67-after-upsized-ipo [2] Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering https://finance.yahoo.com/healthcare/articles/scribe-therapeutics-announces-pricing-upsized-010800484.html [3] Eli Lilly and Company (LLY) https://finance.yahoo.com/quote/LLY/ [4] Scribe secures $129M in a rare gene editing IPO https://finance.yahoo.com/healthcare/articles/scribe-secures-129m-rare-gene-211800640.html [5] Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech https://www.biospace.com/business/early-stage-scribe-wants-to-write-ipo-story-even-as-investors-favor-derisked-portfolios [6] Scribe Enters Collaboration with Lilly’s Prevail to … https://globalgenes.org/raredaily/scribe-enters-collaboration-with-lillys-prevail-to-accelerate-in-vivo-crispr-based-therapies-for-neurological-and-neuromuscular-diseases/ [7] Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing https://endpoints.news/gene-editor-scribe-starts-second-half-ipo-spree-with-129m-listing/ [8] Scribe Therapeutics Achieves Second Success Milestone … https://www.scribetx.com/news/scribe-therapeutics-achieves-second-success-milestone-for-in-vivo-program-in-collaboration-with-eli-lilly-and-company [9] Scribe Therapeutics https://www.scribetx.com/ [10] Scribe Therapeutics IPO Timeline and Financing Details https://forgeglobal.com/scribe-therapeutics_ipo/ [11] Sell or Invest in Scribe Stock Pre-IPO http://www.nasdaqprivatemarket.com/company/scribe/ [12] How to Optimize Content for Perplexity AI: A 2026 Tactical … https://contently.com/2026/02/20/how-to-optimize-content-for-perplexity-ai/ [13] CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO https://medcitynews.com/2026/07/scribe-therapeutics-ipo-crispr-genetic-medicine-pcsk9-ascvd-sctx/ [14] Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Stake Through IPO https://www.marketscreener.com/news/eli-lilly-may-raise-stake-in-scribe-therapeutics-to-10-9-stake-through-ipo-ce7f51dbdb8bf723 [15] Scribe Announces Collaboration with Prevail, a Wholly … https://www.scribetx.com/news/scribe-announces-collaboration-with-prevail-a-wholly-owned-subsidiary-of-lilly-to-accelerate-in-vivo-crispr-based-genetic-medicines-for-neurological-and-neuromuscular-diseases [16] Eli Lilly Stock Price Today | NYSE: LLY Live https://www.investing.com/equities/eli-lilly-and-co [17] Scribe Therapeutics Raises $100M Series B Financing to … https://www.businesswire.com/news/home/20210331005648/en/Scribe-Therapeutics-Raises-$100M-Series-B-Financing-to-Further-Develop-CRISPR-by-Design-Platform-and-Pipeline-of-Breakthrough-Genetic-Medicines [18] Eli Lilly: LLY Stock Price Quote & News https://robinhood.com/us/en/stocks/LLY/ [19] Scribe Therapeutics has put its IPO plans down on paper, … https://x.com/FierceBiotech/status/2079223507913699689 [20] How to Get Cited in Perplexity AI Search Results 2026 https://www.primal.co.th/ai/perplexity/ [21] Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech https://www.biospace.com/business/early-stage-scribe-wants-to-write-ipo-story-even-as-investors-favor-derisked-portfolios [22] Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering https://finance.yahoo.com/healthcare/articles/scribe-therapeutics-announces-pricing-upsized-010800484.html [23] Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Stake Through IPO https://www.marketscreener.com/news/eli-lilly-may-raise-stake-in-scribe-therapeutics-to-10-9-stake-through-ipo-ce7f51dbdb8bf723
U.S. equities closed mixed to lower for the week after a risk-off stretch tied to higher energy prices, rising Treasury yields earlier in the week, and fresh scrutiny on earnings quality and AI spending discipline. By Friday’s close, the S&P 500 finished at 7,411.02, the Dow Jones Industrial Average closed at 52,072.92, and the prior session showed the Nasdaq Composite at 25,137.69 and the Russell 2000 at 2,940.16 as investors rotated away from some higher-beta growth exposure and reassessed inflation risk. The tone of the tape was not outright bearish, but it was more selective. Reuters noted that July trading was increasingly shaped by surging crude prices and inflation sensitivity, while broader market leadership appeared less forgiving of aggressive capital spending narratives, especially across technology and semiconductor names.
Macroeconomic Commentary
The macro backdrop improved on the inflation front, at least in the backward-looking June data. U.S. consumer inflation slowed to 3.5% year over year in June from 4.2% in May, while producer prices unexpectedly fell 0.3% month over month, suggesting price pressures had been easing before the latest Middle East-driven energy spike. Labor data also reinforced the view that the economy remains resilient. Initial jobless claims fell by 22,000 to 187,000 for the week ended July 18, the lowest level since 1969 according to Reuters, a sign that layoffs remain limited even as markets debate whether growth is beginning to cool more unevenly across sectors. That combination, softer inflation but still-tight labor conditions, leaves the Federal Reserve in a difficult position. Reuters reported that elevated inflation had already pushed about half of policymakers at the June meeting to project at least one rate hike by year-end 2026, so investors are now balancing better June inflation data against the possibility that higher oil could re-ignite price pressures into late summer.
Rates, Oil, and Risk
Treasury yields remained central to market sentiment this week. Mid-July readings showed the 10-year Treasury yield near 4.555% and the 2-year near 4.145% after the June inflation reports, underscoring that bond investors have not fully priced out additional Fed tightening. Energy was the swing factor. Reuters said Brent crude moved above $100 per barrel on Thursday for the first time in two months and was still up more than 30% in July by Friday morning, reinforcing the market’s concern that geopolitical risk and higher fuel costs could interrupt the recent disinflation trend. That matters because rising oil changes the market narrative quickly. When energy prices move high enough to threaten consumer spending, transportation margins, and inflation expectations at the same time, equity investors tend to reduce risk first and sort fundamentals second.
Index Performance
Friday’s closing levels provide a clean benchmark for the week’s positioning.
Index
Friday close
Commentary
S&P 500
7,411.02
Large-cap benchmark held above 7,400, but the week reflected fading momentum and more defensive positioning.
Dow Jones Industrial Average
52,072.92
The Dow showed relative resilience as investors favored more cyclical and defensive blue chips over crowded growth trades.
Nasdaq Composite
25,137.69
Tech remained the pressure point as elevated capex expectations and higher yields weighed on sentiment.
Russell 2000
2,940.16
Small caps gave back ground as higher rates and macro uncertainty tempered risk appetite.
Stocks in Focus
Several public companies helped define the week’s tone. Intel (INTC) drew attention after delivering a stronger AI-related outlook, while Micron Technology (MU) benefited earlier in July from a major U.S. investment plan tied to AI memory demand.. At the same time, investors became more demanding across mega-cap and growth-heavy areas, especially where spending commitments appeared ahead of monetization. Reuters also highlighted Meta Platforms (META) in the broader earnings-season conversation, while market commentary pointed to pressure on semiconductor-linked leadership as investors reassessed return-on-capital expectations. The most important takeaway is that macro is back in the driver’s seat. Even strong company-specific stories can get temporarily overwhelmed when oil, yields, inflation expectations, and Fed uncertainty all move at once.
VP Watchlist Updates
Amwell® (NYSE: AMWL)
Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $10.81, +.37% on Friday.
Hudson Pacific Properties (NYSE: HPP)
Hudson Pacific Properties (NYSE: HPP, $15.38, +3.43% on Friday) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.
Eupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. (EPRX, $5.81) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (July 7) the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. “We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology.”
Eupraxia announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”
Modular Medical announced (July 14) announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026. Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology: 1) 97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options, 2) Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually, & 3) 55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.
MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.
NVIDIA (NVDA) closes at $206.84. QumulusAI (Nasdaq: QMLS), a neocloud infrastructure provider purpose-built for the AI computing era, today (July 22) announced a signed two-year agreement, valued at more than $32 million, to supply NVIDIA Blackwell B300 capacity to an AI inference platform provider focused on generative AI applications. The agreement includes renewal options, with capacity expected to come online in the fall of 2026.
The InterGroup Corporation (INTG)
The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $33.97.
LG Display Co., Ltd. (LPL)
LG Display Co., Ltd. (NYSE: LPL, $3.17) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.
Doximity (NYSE: DOCS, $20.42) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.
Doximity, Inc. will report financial results for its fiscal first quarter ended June 30, 2026 after market close on August 6, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com/.
Sable Offshore Corp. (SOC)
Sable Offshore Corp. (SOC, $4.71, +1.07%) is rebooting a controversial but strategically important offshore-pipeline system under federal DPA orders, targeting meaningful production from Platform Hondo while juggling financing needs that could run into the billions and regulatory battles that could reshape California’s energy landscape.
IMAX Corporation (NYSE: IMAX)
IMAX Corporation (NYSE: IMAX, $43.38, +10.52% over the last 5-days) reported (July 23) strong financial results for the second quarter of 2026, demonstrating the value of its unique global entertainment platform and broad content portfolio.Underscoring the power of its global platform, IMAX exceeds consensus expectations and posts strong year-over-year growth for the second quarter across key metrics: Revenue of $103 million, up 12% year-over-year, Strong operating profitability with Net Income margin of 15.5% and Adjusted EBITDA(3) margin of 46.6%, Net income per diluted share of 27 cents, up 35% year-over year and record Q2 Adjusted EPS(2,3) of 43 cents, up 65% year-over-year, & Year-to-date Cash from Operating Activities of $36 million, up 19% year-over-year.
U.S. equities finished lower on Thursday as investors digested a hotter risk backdrop, softer sentiment in mega-cap technology, and a fresh jump in oil and Treasury yields. The move added to concerns that higher energy prices could keep inflation sticky just as the market is looking for more evidence that growth can stay resilient. The Nasdaq Composite closed at 25,137.69, -2.15% led the decline, while the S&P 500 7,408.30,-1.21% and Dow Jones Industrial Average 51,711.65, -.97% also ended the day in the red as traders rotated away from high-multiple growth names and toward more defensive positioning. The session was marked by a clear risk-off tone, with macro pressure and earnings reactions driving most of the tape.
Market Drivers
Treasury yields moved higher, with the 10-year U.S. Treasury yield climbing to 4.675%, the 2-year reaching 4.317%, and the 30-year rising to 5.161%, reinforcing the market’s sensitivity to inflation and rate expectations. At the same time, Brent crude futures pushed above $97 as geopolitical tensions and tanker-attack headlines fed another round of energy-market volatility. Weekly jobless claims also came in lower, signaling that the labor market remains relatively firm even as the broader economy faces crosscurrents from higher borrowing costs and energy prices. That combination—solid labor data, firmer yields, and more expensive oil—can be a difficult mix for stocks because it reduces the odds of rapid Federal Reserve easing.
Intel Earnings Focus
Intel Corporation (NASDAQ: INTC) was one of the day’s most closely watched corporate stories after reporting second-quarter 2026 revenue of $16.1 billion, up 25% year over year, and issuing third-quarter revenue guidance of $15.8 billion to $16.8 billion. Intel said the quarter reflected its strongest revenue growth in more than fifteen years, helped by AI-driven compute demand and better execution. Even so, Intel also reported a GAAP loss of $2.16 per share, underscoring that the turnaround story is still in progress despite stronger top-line momentum. For investors, the key takeaway is that Intel’s AI and foundry narrative is improving, but the earnings profile remains uneven as the company continues to invest heavily. INTC shares rose 3.92% in the aftermarket.
VP Watchlist Updates
Amwell® (NYSE: AMWL)
Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $10.77.
Hudson Pacific Properties (NYSE: HPP)
Hudson Pacific Properties (NYSE: HPP, $14.87, +2.98%) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.
Eupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. (EPRX, $6.30) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (July 7) the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. “We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology.”
Eupraxia announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”
Modular Medical announced (July 14) announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026. Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology: 1) 97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options, 2) Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually, & 3) 55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.
MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.
NVIDIA (NVDA) closes at $208.76, -1.56%. QumulusAI (Nasdaq: QMLS), a neocloud infrastructure provider purpose-built for the AI computing era, today (July 22) announced a signed two-year agreement, valued at more than $32 million, to supply NVIDIA Blackwell B300 capacity to an AI inference platform provider focused on generative AI applications. The agreement includes renewal options, with capacity expected to come online in the fall of 2026.
The InterGroup Corporation (INTG)
The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $34.88, +2.53%.
LG Display Co., Ltd. (LPL)
LG Display Co., Ltd. (NYSE: LPL, $3.37, +2.43%) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.
Doximity (NYSE: DOCS, $20.45) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.
Doximity, Inc. will report financial results for its fiscal first quarter ended June 30, 2026 after market close on August 6, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com/.
Sable Offshore Corp. (SOC)
Sable Offshore Corp. (SOC, $4.66, +6.39%) is rebooting a controversial but strategically important offshore-pipeline system under federal DPA orders, targeting meaningful production from Platform Hondo while juggling financing needs that could run into the billions and regulatory battles that could reshape California’s energy landscape.
IMAX Corporation (NYSE: IMAX)
IMAX Corporation (NYSE: IMAX, $43.96, +11.86%) today reported strong financial results for the second quarter of 2026, demonstrating the value of its unique global entertainment platform and broad content portfolio.Underscoring the power of its global platform, IMAX exceeds consensus expectations and posts strong year-over-year growth for the second quarter across key metrics: Revenue of $103 million, up 12% year-over-year, Strong operating profitability with Net Income margin of 15.5% and Adjusted EBITDA(3) margin of 46.6%, Net income per diluted share of 27 cents, up 35% year-over year and record Q2 Adjusted EPS(2,3) of 43 cents, up 65% year-over-year, & Year-to-date Cash from Operating Activities of $36 million, up 19% year-over-year.
Hims & Hers Health, Inc. (HIMS)
Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results.
Jamie Dimon’s latest interview had the kind of calm, polished menace Wall Street loves: the economy is sturdy, AI is real, bonds are not his favorite date, and government deficits are the sort of thing that tend to arrive uninvited and stay too long. He did not sound apocalyptic; he sounded like a banker who has already checked the exits twice and noticed the smoke machine. That combination makes for good television and even better portfolio discipline.
Bonds, Deficits and the Return of Gravity
Dimon said plainly that he would not buy long-dated government bonds here and argued that inflation, deficits and interest rates still leave little upside in the bond market. He also warned that the world is carrying unusually high debt and deficit burdens, which history tends to treat the way a patient doctor treats a suspicious rash: with concern, a clipboard and a follow-up appointment. The point was not panic; it was humility. Markets may be efficient, but they are not clairvoyant, and fiscal reality has a habit of eventually collecting its invoice.
AI: Powerful, Expensive, and Not Promptly Grateful
On AI, Dimon was optimistic about long-term value creation, while cautioning that the payoff will probably take longer than investors expect. That matters because markets routinely fall in love with the speed of a story and then resent the pace of the cash flow. His framing was clear: AI can be transformative, but not every company buying chips, models and cloud capacity will receive a hero’s welcome from the earnings call. In investor terms, that means the winners may be fewer than the headlines suggest, but the winners may be enormous.
JPMorgan’s Quiet Advantage
The interview also reinforced why JPMorgan Chase (JPM) remains such a formidable institution: strong capital, abundant liquidity, and a culture that has learned to expect turbulence instead of romanticize it. Dimon’s description of crisis-era decision-making was especially telling, because it framed leadership as stress testing rather than bravado. In a market full of CEOs auditioning for certainty, that is refreshingly adult.
The Lesson
For investors, the useful takeaway is not just Dimon’s macro view; it is the structure behind it. The best businesses and the best stocks tend to have catalyst density, story clarity, financial trajectory, liquidity and governance discipline working in their favor. That is why the market rewards companies that can explain themselves in one clean sentence and survive a bad month without needing an interpretive dance routine to reassure shareholders. When those factors align, capital follows.
Why This Matters Now
The interview lands at a time when the market appears comfortable enough to be dangerous, which is often when the best risk managers become popular again. Dimon’s message does not argue against equities in general, but it does argue against complacency, especially in duration-sensitive assets and in parts of the equity market priced for perfection. The practical reading is simple: stay invested, stay selective, and do not confuse resilience with immunity.
Learn More
SEO-Friendly Headline Options
Jamie Dimon on Bonds, AI and Deficits: Why Wall Street Should Stay Alert
JPMorgan’s Jamie Dimon Warns on Bonds, Deficits and the AI Payoff Timeline
Jamie Dimon’s Market View: AI Is Real, Bonds Are Not Cheap, and Deficits Matter
Why Jamie Dimon’s Latest Comments Matter for JPM, Bonds and the S&P 500
Wall Street is getting three reminders at once: geopolitics can still move oil and yields, defense demand remains durable, and medtech innovation is still finding ways to surprise investors. The result is a market story that feels less like a single headline and more like a three-act play with decent cash flow and an occasional plot twist.
Bond Market Whisper
The 10-year Treasury yield climbed to about 4.7%, its highest level since January 2025, as oil surged above $100 a barrel and inflation fears reawakened. In market terms, that is the bond market politely clearing its throat and then refusing to stop talking. Higher yields matter because they press on valuations, borrowing costs, and mortgage rates all at once, which is why the move landed with more force than a typical daily wobble. The message is simple: when oil gets expensive, nobody gets to pretend the macro backdrop is a Hallmark movie.
Lockheed’s Signal
Lockheed Martin (NYSE: LMT) delivered a strong second quarter, with sales up about 11% to roughly $20.1 billion, net earnings of $1.8 billion, and backlog reaching a record $230.4 billion. Investors liked the setup enough to push the stock sharply higher, helped by raised 2026 guidance and a fresh reminder that governments tend to keep buying defense when the world gets noisy. That backlog is the kind of number that makes long-term investors sit up straighter. It also suggests the company is not just selling hardware; it is selling visibility, which in a market obsessed with uncertainty is close to a luxury good.
Modular Medical’s Pivot
Modular Medical (NASDAQ: MODD) announced the formation of its Pivot Innovation Council and named Robert Gabbay, MD, PhD, FACP as chairman, adding another layer of credibility around its Pivot insulin delivery platform. Dr. Gabbay is internationally recognized for his work transforming diabetes care through innovative delivery models, population health strategies, and quality improvement initiatives. Over the course of his career, Dr. Gabbay has held numerous leadership roles dedicated to advancing diabetes care nationally and globally, including executive leadership positions with the American Diabetes Association and Harvard’s Joslin Diabetes Center. His work has helped define and implement patient-centered care models across hundreds of clinical practices and has influenced healthcare delivery strategies worldwide. Dr. Gabbay is internationally recognized for his work transforming diabetes care through innovative delivery models, population health strategies, and quality improvement initiatives. Over the course of his career, Dr. Gabbay has held numerous leadership roles dedicated to advancing diabetes care nationally and globally, including executive leadership positions with the American Diabetes Association and Harvard’s Joslin Diabetes Center. His work has helped define and implement patient-centered care models across hundreds of clinical practices and has influenced healthcare delivery strategies worldwide. “The formation of the Pivot Innovation Council represents an important milestone for us, as we deepen our engagement with clinicians and healthcare stakeholders,” said Jeb Besser, CEO. “By bringing together leading experts across disciplines, we are creating a forum that we believe will help ensure our solutions address real-world clinical needs and deliver meaningful value to providers, health systems, and patients. We are honored to welcome Dr. Gabbay as chair of the Pivot Innovation Council,” continued Mr. Besser. “His unique combination of clinical expertise, healthcare transformation leadership, and deep experience advancing patient-centered care models will be invaluable as we continue to build clinical evidence, strengthen provider engagement, and expand our impact on patient outcomes.” The move follows earlier FDA 510(k) clearance for Pivot, which opened the door to U.S. commercial sales and gave the story a more tangible near-term revenue path. For investors watching diabetes tech, this matters because execution is now the point, not just aspiration. Modular Medical is trying to turn a good product story into an adoption story, and in medtech that is where the real drama begins—after the press release, not before it.
The Thread
The common thread across all three headlines is that the market is rewarding businesses with either durable demand, strategic necessity, or a real commercial catalyst. Defense looks supported by backlog and replenishment needs, rates are reacting to inflation pressure, and medtech is showing that regulatory progress can still create meaningful investor interest. For traders and long-term investors alike, this is a reminder that the best stories are often the least subtle: the world gets more uncertain, Treasury yields react, defense budgets look sturdier, and selective healthcare innovators keep trying to solve expensive problems more elegantly than the incumbents. That is not exactly poetry, but it does tend to trade well.
The Sources
Yahoo Finance — Lockheed Martin reports second quarter results: Link
Yahoo Finance — 10-year Treasury yield climbs to highest level since January 2025 as $100 oil sparks inflation fears: Link
Yahoo Finance — Modular Medical announces formation of Pivot Innovation Council: Link
U.S. stocks finished Wednesday with a mixed but relatively calm tone: the S&P 500 (^GSPC) rose 0.1% to 7,498.96, the Dow Jones Industrial Average (^DJI) slipped less than 0.1% to 52,218.58, and the Nasdaq Composite (^IXIC) fell 0.6% to 25,690.90. The move reflected a market that stayed resilient overall, but clearly leaned away from mega-cap growth as oil prices and pre-earnings caution weighed on sentiment.
Closing action
The clearest story in Wednesday’s close was divergence. The S&P 500 (^GSPC) held close to unchanged, the Dow (^DJI) managed only a fractional loss, and the Nasdaq (^IXIC) underperformed as traders stepped back from tech ahead of Alphabet (GOOGL) and Tesla (TSLA) earnings. That kind of rotation matters because it suggests the market is still willing to buy strength, but it is not yet ready to reward high-multiple growth stocks indiscriminately.
Market tone
Higher oil prices ($86.48, +2.14%) kept pressure on the tape, helping explain why the broader market could not extend Tuesday’s stronger rally. Even so, the damage was limited, which points to an orderly pullback rather than a broad risk-off break. For investors, that combination usually signals a market that is consolidating gains while waiting for the next major catalyst.
What it means
The takeaway is that Wednesday’s close was more about positioning than panic. Large-cap indices held up better than the Nasdaq (^IXIC), showing that defensives and lower-beta leadership still have a role when crude is firm and earnings risk is elevated. That makes Thursday’s follow-through especially important for confirming whether the recent AI-driven advance can keep broadening beyond the biggest tech names.
Biotech note
In healthcare, Repligen (RGEN, $140.09, +2.26%) moved to acquire BioLife Solutions (BLFS, $31.15, +6.71%) in a deal valued at about $1.5 billion, adding another strategic M&A headline to a market already digesting earnings and macro pressure. For biotech and life-sciences readers, that is the most relevant sector-specific catalyst in this tape and a reminder that deal flow remains a meaningful source of alpha.
VP Watchlist Updates
Amwell® (NYSE: AMWL)
Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $11.66.
Hudson Pacific Properties (NYSE: HPP)
Hudson Pacific Properties (NYSE: HPP, $14.44) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.
Eupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. (EPRX, $6.42, +.63%) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (July 7) the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. “We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology.”
Eupraxia announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”
Modular Medical announced (July 14) announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026. Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology: 1) 97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options, 2) Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually, & 3) 55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.
MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.
MODD announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”
The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $34.60.
LG Display Co., Ltd. (LPL)
LG Display Co., Ltd. (NYSE: LPL, $3.29, +.92%) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.
Doximity (NYSE: DOCS, $20.49) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.
Sable Offshore Corp. (SOC)
Sable Offshore Corp. (SOC, $4.38, +4.53%) is rebooting a controversial but strategically important offshore-pipeline system under federal DPA orders, targeting meaningful production from Platform Hondo while juggling financing needs that could run into the billions and regulatory battles that could reshape California’s energy landscape.
Repligen’s (REGN) $1.5 billion purchase of BioLife Solutions (BLFS) lands in the middle of a biotech M&A market that is getting bigger, faster, and a bit more strategic than the old “buy the science and hope for the best” model. The deal puts RGEN squarely in the cell-therapy workflow business, while also highlighting a broader pattern: bioprocessing is drawing capital for its recurring revenue, mission-critical tools, and less melodramatic earnings profile than many drug-development bets.
The Deal Itself
Repligen Corp. (RGEN) said it will acquire BioLife Solutions (BLFS) in a cash-and-stock transaction valued at about $1.5 billion. BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen for each BioLife share, implying a value of about $31 per share and a premium of roughly 6.2% to BioLife’s last close. The companies’ boards unanimously approved the transaction, which is expected to close in the fourth quarter of 2026, pending regulatory and shareholder approvals.
Why Repligen Wanted It
This is not just a bolt-on; it is a strategic move deeper into the cell-therapy supply chain. BioLife brings biopreservation media, cell-processing tools, and a high-margin consumables business that Repligen says should expand its presence in a fast-growing market. In Wall Street language, Repligen is buying “mission-critical technologies”; in plain English, it is buying the stuff that keeps fragile cells alive long enough to become a commercial product.
The Financial Logic
Repligen expects the deal to add to adjusted earnings and generate at least $20 million in first-year savings from cost cuts and efficiency gains. Investing.com’s report added that the transaction is expected to be accretive by at least 5 cents per share in year one and at least 25 cents in year two, with synergies rising to more than $30 million in year two. That makes the deal look less like a speculative swing and more like a disciplined effort to widen margins while increasing exposure to recurring revenue.
Why Bioprocessing Is Hot
Bioprocessing M&A is increasingly about owning the picks-and-shovels layer of biotech: single-use systems, cold-chain tools, consumables, and digital workflow products. Recent industry coverage points to a recovery in bioprocessing suppliers after post-COVID destocking, with growth supported by private equity interest and renewed demand for manufacturing tools. That makes these assets appealing because they can generate revenue even when the broader biotech mood is moody, which is often before the coffee is finished brewing.
How It Compares With Broader Biotech
Broader biotech M&A is also strong, but its center of gravity is different. Large-scale biotech and biopharma deals are being driven by patent cliffs, pipeline replenishment, and the need to buy de-risked assets or platform technologies with therapeutic upside. JPMorgan (JPM) cited $96 billion in biopharma and medtech M&A in H1 2026, while BioBucks reported $149 billion across 49 biotech control transactions in H1 2026, showing just how heated the broader market has become.
What Separates The Two
Bioprocessing deals tend to be more industrial, more recurring-revenue oriented, and less dependent on binary clinical outcomes. Broader biotech deals can offer more upside, but they carry much heavier scientific, regulatory, and valuation risk because the payoff often depends on future trial data or commercialization success. In short, bioprocessing is about owning the infrastructure; broader biotech is about buying the next possible drug, delivery platform, or growth engine.
Takeaway
The Repligen-BioLife deal is a clean example of where the market is rewarding strategy over spectacle. It combines a reasonable premium, clear synergy targets, and a business model tied to the operational backbone of cell therapy. Meanwhile, the broader M&A backdrop suggests the sector is moving beyond only blockbuster headline deals and into a more layered market where platform assets, mid-cap buyers, and infrastructure providers are all active.
The Sources
[1] Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business https://finance.yahoo.com/healthcare/articles/repligen-buy-cell-therapy-maker-101826707.html [2] Bioprocessing suppliers see growth After COVID destocking https://www.bioprocessintl.com/global-markets/single-use-and-digital-tools-sit-firm-on-the-pe-bioprocess-buy-list [3] Biotech M&A Surge Seen as Going Beyond Blockbuster Deals https://www.bloomberg.com/news/articles/2026-07-09/biotech-m-a-surge-seen-as-going-beyond-blockbuster-deals [4] Repligen to buy BioLife in $1.5 billion deal to expand cell … https://www.reuters.com/legal/transactional/repligen-buy-biolife-solutions-15-billion-deal-2026-07-22/ [5] Repligen to acquire BioLife Solutions for $1.5 billion https://www.investing.com/news/company-news/repligen-to-acquire-biolife-solutions-for-15-billion-93CH-4805094 [6] Repligen to Buy BioLife Solutions for $1.5 Billion — Update https://www.marketwatch.com/story/repligen-to-buy-biolife-solutions-for-1-5-billion-update-6f5dd598 [7] Repligen builds in cell therapy with $1.5bn BioLife takeover https://pharmaphorum.com/news/repligen-builds-cell-therapy-15bn-biolife-takeover [8] Biolife Solutions: Home https://biolifesolutions.com/ [9] The new rules of biopharma M&A: 4 trends driving dealmaking this year https://www.fiercebiotech.com/biotech/new-rules-biopharma-ma-4-trends-driving-deal-making-year [10] Bioprocessing Segment Spotlight Summer 2023 https://hl.com/media/3m5bkutv/bioprocessing-segment-spotlight-summer-2023.pdf [11] Biotech M&A H1 2026 Report — $149B Across 49 Deals https://www.biobucks.co/research-hub/ma-report-h1-2026 [12] ‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid https://www.cnbc.com/2026/06/04/biotech-ma-dealmaking-pharma-106-billion.html [13] Pharmaceutical and life sciences: US Deals 2026 midyear … https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html [14] Biopharma and Medtech Deal Reports for Q2 2026 https://www.jpmorgan.com/insights/markets-and-economy/outlook/biopharma-medtech-deal-reports [15] Key trends shaping biopharma dealmaking in 2025 https://www.mckinsey.com/industries/life-sciences/our-insights/the-synthesis/pulse-check-key-trends-shaping-biopharma-dealmaking-in-2025 [16] Life Sciences M&A Trends Report 2026 https://www.deloitte.com/us/en/industries/life-sciences-health-care/articles/mergers-and-acquisitions-trends-survey-life-sciences.html [17] Repligen Corporation Common Stock (RGEN) https://www.nasdaq.com/market-activity/stocks/rgen [18] BioLife Solutions, Inc. Common Stock (BLFS) https://www.nasdaq.com/market-activity/stocks/blfs [19] NASDAQ:MRVI – Maravai LifeSciences Holdings, Inc. https://www.tradingview.com/symbols/NASDAQ-MRVI/ [20] Repligen to acquire BioLife in cash–stock merger | RGEN … https://www.stocktitan.net/sec-filings/RGEN/425-repligen-corp-business-combination-communication-3cf723825e52.html [21] Repligen To Acquire BioLife Solutions In $1.5 Billion Cash- … https://www.finanzen.ch/nachrichten/aktien/repligen-to-acquire-biolife-solutions-in-$1-5-billion-cash-and-stock-deal-1036350865 [22] Repligen Corp https://www.reuters.com/company/repligen-corp/ [23] Repligen va racheter BioLife, spécialiste de la thérapie … https://www.boursorama.com/bourse/actualites-amp/repligen-va-racheter-biolife-specialiste-de-la-therapie-cellulaire-dans-le-cadre-d-une-operation-de-1-5-milliard-de-dollars-8b20ea2514ab5b9a8acb1ef31e62046f [24] Repligen to buy cell therapy maker BioLife in $1.5 billion deal https://www.marketscreener.com/news/repligen-to-buy-cell-therapy-maker-biolife-in-1-5-billion-deal-ce7f51d9d88af222 [25] Biolife Is Said to Have Drawn Takeover Interest From … https://www.bloomberg.com/news/articles/2026-06-26/biolife-is-said-to-have-drawn-takeover-interest-from-repligen [26] Repligen to Acquire BioLife Solutions in Cash-and-Stock … https://www.tradingview.com/news/tradingview:22edf095306eb:0-repligen-to-acquire-biolife-solutions-in-cash-and-stock-deal-11-25-plus-0-1442-shares-per-share/
U.S. stocks rebounded on Tuesday, July 21, 2026, after Monday’s risk-off tone, with futures and sentiment improving as investors leaned into earnings strength and a modest easing in some geopolitical pressure. The best read for today is a “rotation-within-risk” tape: cyclicals and rate-sensitive names remain choppy, while AI, semis, and select mega-cap tech are still doing the heavy lifting.
Market tone
Monday’s pullback was driven by concerns tied to healthcare and industrial weakness, plus the spillover from higher oil and Middle East uncertainty, while Tuesday’s setup turned more constructive as traders looked ahead to fresh earnings catalysts. The Dow Jones Industrial Average rose 385.38 points, or 0.74%, with the S&P 500 up 0.89% and the Nasdaq Composite up 1.29% in a strong rebound session.
Macro backdrop
The macro driver today remains the same mix of higher energy prices, geopolitical risk, and rate uncertainty. Multiple market briefs said the U.S.-Iran conflict and oil-supply concerns were still influencing risk appetite, while crude up 2.51% at $84.55/bbl had already pushed higher enough to keep inflation expectations sticky. Treasury yields were also cited as a pressure point, with the 10-year around 4.59%-4.60% in the broader market commentary, which tends to keep pressure on valuation-sensitive sectors.
Sector focus
Semiconductors and AI infrastructure remain the cleanest leadership theme, supported by earnings expectations and analyst optimism. Market commentary highlighted names such as NVIDIA Corporation (NVDA), Advanced Micro Devices, Inc. (AMD, $544.43, +8.11%), Intel Corporation (INTC, $105.45, +8.64%), and Microsoft Corporation (MSFT) as beneficiaries of the ongoing AI capex narrative, while the broader tech group was helped by rebound buying. On the softer side, healthcare and industrials were part of Monday’s laggard mix, showing that defensive leadership has not been stable enough to offset macro volatility.
Stock-specific catalysts
Today’s analyst-call flow added company-specific dispersion. Adobe Inc. (ADBE) was downgraded, Datadog, Inc. (DDOG) was cut to Hold, Salesforce, Inc. (CRM) was downgraded, while Microsoft Corporation (MSFT) and Fortinet, Inc. (FTNT) received more constructive calls.
VP Watchlist Updates
Amwell® (NYSE: AMWL)
Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $12.48.
Hudson Pacific Properties (NYSE: HPP)
Hudson Pacific Properties (NYSE: HPP, $14.56) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.
Eupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. (EPRX, $6.38, +2.24%) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (July 7) the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. “We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology.”
Eupraxia announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”
Modular Medical announced (July 14) announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026. Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology: 1) 97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options, 2) Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually, & 3) 55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.
MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.
MODD announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”
The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $38.02.
LG Display Co., Ltd. (LPL)
LG Display Co., Ltd. (NYSE: LPL, $3.26, +2.19%) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.
Doximity (NYSE: DOCS, $21.11) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.
Sable Offshore Corp. (NYSE: SOC) and Similarweb Ltd. (NYSE: SMWB) add two very different—but highly instructive—chapters to the evolving energy and data narrative already being written by Vivakor Inc. (NASDAQ: VIVK), Exxon Mobil Corporation (NYSE: XOM) and Shell plc (NYSE: SHEL).
Offshore Barrels, Onshore Drama: Sable’s Santa Ynez Moment
While Vivakor is busy scaling recurring physical crude flows across Cushing, the Bakken and the Permian, Sable Offshore Corp. has been orchestrating a high-stakes restart of hydrocarbons from the Santa Ynez Unit off California’s Central Coast. In March 2026, at the direction of the U.S. Secretary of Energy under authorities delegated by President Donald J. Trump through the Defense Production Act, Sable resumed transportation of oil through the federally regulated Santa Ynez Pipeline System, reactivating flows from offshore platforms to onshore processing and downstate refining. Corporate updates suggest that Sable’s Platform Hondo is expected to ramp to approximately 10,000 gross barrels per day as operations normalize, part of a broader restart that has already seen oil sales commence from the pipeline system and production flow restored following extensive anomaly repair programs and hydrotests. This operational progress has come alongside a flurry of capital-markets activity—offerings of common stock and convertible senior notes, term loan amendments, and conference calls aimed at explaining how SOC intends to finance what could ultimately require around $1.7 billion to fully execute its Santa Ynez project vision. The sophisticated wrinkle, of course, is that Sable’s engineering ambition is matched by legal and regulatory theater: multiple cease-and-desist orders, an $18 million fine from the California Coastal Commission, and ongoing litigation in state and federal courts over pipeline jurisdiction and environmental compliance. For investors, SOC offers a concentrated case study in how federal energy policy, state climate politics, and offshore infrastructure collide—creating a risk-reward profile where barrels, cash flows, and court decisions share equal billing in the valuation model.
Vivakor and Sable: Different Scales, Shared Physics
Viewed together, Vivakor and Sable represent two ends of the energy spectrum: VIVK building a diversified platform of recurring physical crude marketing across multiple basins, and SOC focusing intensely on a single offshore complex and its associated pipeline and financing stack. Vivakor’s four new recurring crude contracts expand marketed volumes to roughly 300,000 barrels per month and push annualized commercial activity beyond $700 million, with an eye toward $1 billion-plus in crude-related deals supported by credit facilities and logistics networks. Sable, by contrast, is moving from operational zero to tens of thousands of barrels per day in one highly contested geography, relying on DPA-driven federal support and capital markets access to restart and potentially reconfigure its Santa Ynez value chain. For investors, the parallel is clear: whether you are looking at a micro-cap marketer like VIVK or a more sizeable offshore operator like SOC, the durable value often lies not in headline oil prices, but in who controls the flows, the financing, and the regulatory narrative around key assets. Exxon Mobil and Shell—XOM and SHEL/SOC—serve as the scaling backdrop: integrated majors tightening their own supply-chain integration and energy-transition roadmaps while still depending on a mosaic of third-party marketers, offshore operators, and pipeline owners to keep refineries, petrochemical plants, and trading books fed with physical barrels. In that sense, VIVK and SOC are not curiosities; they are part of the operating fabric that allows the giants to remain giant.
Similarweb: Data Gravity for the Energy Trade
If Vivakor and Sable manage the crude and the steel, Similarweb Ltd. quietly manages the digital exhaust that increasingly drives how investors, traders, and even energy companies themselves make decisions. Similarweb (SMWB) recently reported that its Annual Recurring Revenue has surpassed $300 million, supported by two new multi-year enterprise contracts each representing seven-figure ARR commitments—numbers that put it firmly in the camp of scaled, sticky SaaS-like data businesses. First quarter 2026 results came in at the top end of guidance for both revenue and non-GAAP operating profit, marking the tenth consecutive quarter of positive normalized free cash flow and prompting management to raise the lower end of the 2026 guidance range. Multi-year subscriptions now account for 64% of ARR, up from 52% in 2025, while remaining performance obligations climbed 18% year-over-year to nearly $298 million as of March 31, 2026. Underneath those numbers is an expanding ecommerce and digital intelligence offering, plus a planned CEO transition that suggests SMWB is actively positioning itself for its next phase of growth. For energy-focused investors, the relevance is straightforward: as companies like VIVK and SOC navigate customer acquisition, investor relations, regulatory messaging, and market positioning, digital data on traffic flows, engagement patterns, and competitive benchmarks becomes part of the same toolkit as pipeline maps and reservoir models. SMWB’s platform is precisely the sort of resource that can help an energy marketer understand which press release actually moved the needle, which investor deck captured attention, and which regulatory headline is driving search and social chatter.
Energy, Data, and the Investor’s Edge
Put it all together, and the story becomes investor-magnetic:
Vivakor (VIVK) is scaling recurring physical crude marketing across U.S. hubs with $700 million-plus in annualized commercial activity and ambitions for more, supported by credit intermediation and logistics assets.
Sable Offshore Corp. (SOC) is rebooting a controversial but strategically important offshore-pipeline system under federal DPA orders, targeting meaningful production from Platform Hondo while juggling financing needs that could run into the billions and regulatory battles that could reshape California’s energy landscape.
Exxon Mobil (XOM) and Shell (SHEL) are refining integration and transition strategies that implicitly rely on agile operators and marketers like VIVK and SOC to keep physical barrels moving efficiently and compliantly.
Similarweb (SMWB) is quietly becoming the data gravity well around which digital decision-making orbits, with ARR above $300 million, expanding multi-year contracts, and a decade’s worth of positive normalized free cash flow to fund further innovation in web and ecommerce intelligence.
In a market obsessed with narratives, the sophisticated humor is that some of the most compelling stories now live at the intersection of offshore platforms, crude marketing desks, courtrooms, and digital analytics dashboards. For investors willing to bridge those worlds, tickers like VIVK, SOC, XOM, SHEL, and SMWB offer not just exposure to energy and data, but to the very infrastructure—physical and digital—that will decide who actually wins the long game of capital allocation in an economy that still runs on barrels and increasingly runs on bytes.
